BNO-1355

BNO-1355 is an investigational oral herbal dry extract developed by Bionorica SE, a German pharmaceutical company specializing in phytotherapeutics. It is currently in Phase II clinical development for the treatment of seasonal allergic rhinitis (hay fever). The drug is being evaluated for both acute symptom relief and prophylactic efficacy using allergen challenge models in adults. As a phytopharmaceutical, BNO-1355 is a complex mixture of plant-derived compounds intended to modulate the allergic inflammatory response. While the specific botanical source and molecular mechanism of action are proprietary, the drug is part of Bionorica's portfolio of evidence-based herbal medicines developed through their 'phytoneering' approach.